| Name | Title | Contact Details |
|---|
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists` clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry.
Helix Medical Communications is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our dedicated teams work together to create healthier communities by building strong partnerships. We connect expertise to inspired ideas, products and services while creating a relevant, memorable difference in the lives of our clients, customers and employees. Our dental division provides differentiated products, services and solutions throughout North America. We partner with oral health professionals to create an improved patient experience and practice lifestyle. Our animal health division provides consumable supplies, equipment, software, diagnostic products, vaccines and pharmaceuticals to both companion animal and large animal markets in the U.S. and U.K.
Smith & Nephew is a global advanced medical technology business. We support healthcare professionals in more than 100 countries to improve the quality of life for their patients. Since 1856, when our founder T.J. Smith developed a new method for refining cod liver oil, and in World War One when his nephew led the supply of wound care products, to the present day, Smith & Nephew continues to pioneer health solutions. Through our market leadership positions in Sports Medicine, Trauma, Orthopaedic Reconstruction and Advanced Wound Management, our 16,000 employees continue to improve outcomes and expand access, constantly striving to create value for healthcare professionals, patients, payers and shareholders. Annual sales in 2016 were more than $4.6 billion. We are a constituent of the UK’s FTSE100 and our shares are traded on London Stock Exchange and through American Depository Receipts on the New York Stock Exchange We have leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma. We have almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. We are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)
Bioject Medical Technologies Inc. is a leader in the development of needle-free injection therapies with over 25 years of experience improving the administration of liquid medications; pharmaceuticals, vaccines, and biologics. Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. From its early work focused on improving the characteristics of these delivery systems, the Company has created a broad technology platform for delivering a wide range of medications and vaccines to the subcutaneous, intramuscular and intradermal depths. Bioject has developed a portfolio of injection systems based on its core technology, the foundation for which is more than 80 issued and pending patents and an extensive body of technical know-how. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing inexpensive, pre-filled, disposable injection systems. Further validating its technology, Bioject and its partners have the largest volume of published studies using needle-free injection technology systems. Bioject's strategy is to form strategic partnerships with pharmaceutical, biotechnology, and animal health companies. The result is mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of their injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies. Bioject's products are also used in public health, Physicians offices, and in cutting edge biomedical research at leading institutions around the globe.